Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome (TOYOTA)

18. december 2014 opdateret af: University of Waterloo
Sjogren's Syndrome is an autoimmune condition in which the body attacks its own glands in the body. Some of these glands are responsible for providing lubrication for the eye. As a result, individuals with Sjogren's Syndrome often experience dry eye. Recently, a study had shown that dry eye symptoms were improved by removing debris and old skin cells along the eyelid margin. This technique is called eyelid debridement-scaling. The purpose of this study is to determine how well this technique works in improving dry eye signs and symptoms in individuals with Sjogren's Syndrome.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

14

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Canada
    • Ontario
      • Waterloo, Ontario, Canada, N2L 3G1
        • Centre for Contact Lens Research, University of Waterloo

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

17 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Is at least 17 years of age and has full legal capacity to volunteer;
  • Has read and signed an information consent letter;
  • Is willing and able to follow instructions and maintain the appointment schedule;
  • Is diagnosed with Sjogren's Syndrome;
  • Meibomian gland score of ≤ 9 (out of 15);
  • OSDI ≥ 23;
  • Willing to maintain the use of OTC medications throughout the course of the study
  • Have not worn contact lenses within the past 3 years

Exclusion Criteria:

  • Is participating in any concurrent clinical or research study;
  • Has any known active* ocular disease and/or infection;
  • Has a systemic condition, other than Sjogren's Syndrome and its associated conditions, that in the opinion of the investigator may affect a study outcome variable;
  • Is using any systemic or topical medications, other than those indicated for Sjogren's Syndrome and its associated conditions, that in the opinion of the investigator may affect a study outcome variable;
  • Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
  • Is pregnant, lactating or planning a pregnancy at the time of enrolment;
  • Is aphakic;
  • Has undergone refractive error surgery; * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Styring
Ingen behandling
Eksperimentel: Lid debridgement scaling
Perform lid debridgement scaling
Procedure: Lid debridgement scaling

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Meibomisk kirtelscore (MGS)
Tidsramme: Baseline
Før behandling (hvis relevant). Skala 0-3. 0: ingen sekretion, 1: inspisseret (tandpasta), 2: uklar med snavs, 3: klar
Baseline
Meibomske kirtel, der giver væskesekretioner (MGYLS)
Tidsramme: Baseline
Før behandling (hvis relevant). MGYLS er antallet af kirtler med MGS grad 2 eller højere.
Baseline
Ocular Surface Disease Index Score (OSDI)
Tidsramme: Baseline
Før behandling (hvis relevant). OSDI er et spørgeskema, der består af 12 spørgsmål om øjenirritation og virkningen af ​​tørre øjne på synet. For hvert spørgsmål tjekker deltagerne en score mellem 0 og 4, hvor 0 er lig med "ingen af ​​tiden" og 4 er lig med "hele tiden". OSDI-score beregnes i henhold til: OSDI = [(summen af ​​score for alle besvarede spørgsmål)*100] / [(samlet antal besvarede spørgsmål)*4]. Det mulige område for OSDI-score er 0 til 100.
Baseline
Meibomian gland score (MGS)
Tidsramme: 1 month after baseline and/or treatment
Scale 0-3. 0: no secretion, 1: inspissated (toothpaste), 2: cloudy with debris, 3: clear
1 month after baseline and/or treatment
SICCA Ocular Staining Score
Tidsramme: Baseline
Prior to treatment (if applicable). Based on corneal and conjunctival staining. Total scores range 0 to 12 with 0 being no staining and 12 being high staining.
Baseline
SICCA Ocular Staining Score
Tidsramme: 1 month after baseline and/or treatment
Based on corneal and conjunctival staining. Total scores range 0 to 12 with 0 being no staining and 12 being high staining.
1 month after baseline and/or treatment
Ocular Surface Disease Index Score (OSDI)
Tidsramme: 1 month after baseline/treatment
The OSDI is a questionnaire that consists of 12 questions about ocular irritation and the effect of dry eye on vision. For every question, participants check a score between 0 and 4, where 0 equals "none of the time" and 4 equals "all of the time". OSDI scores are calculated according to: OSDI = [(sum of scores for all questions answered)*100] / [(total number of questions answered)*4]. The possible range of the OSDI score is 0 to 100.
1 month after baseline/treatment
Meibomian gland yielding liquid secretions (MGYLS)
Tidsramme: 1 month after baseline/treatment
MGYLS is the number of glands with MGS grade 2 or higher.
1 month after baseline/treatment
Symptom Assessment iN Dry Eye score
Tidsramme: Baseline
Prior to treatment (if applicable). A short questionnaire based on a visual analog scale (VAS) to quantify the frequency and severity of symptoms of dry eye syndrome. The "Symptom Assessment iN Dry Eye" (SANDE) questionnaire utilizes a 100 mm horizontal VAS technique to quantify patient symptoms of ocular dryness and/or irritation.
Baseline
Symptom Assessment iN Dry Eye score
Tidsramme: 1 month after baseline and/or treatment
A short questionnaire based on a visual analog scale (VAS) to quantify the frequency and severity of symptoms of dry eye syndrome. The "Symptom Assessment iN Dry Eye" (SANDE) questionnaire utilizes a 100 mm horizontal VAS technique to quantify patient symptoms of ocular dryness and/or irritation.
1 month after baseline and/or treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University of Waterloo

Samarbejdspartnere

Sjogren's Society of Canada

Efterforskere

  • Ledende efterforsker: Lyndon Jones, PhD, CCLR, University of Waterloo

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. august 2014

Primær færdiggørelse (Faktiske)

1. november 2014

Studieafslutning (Faktiske)

1. november 2014

Datoer for studieregistrering

Først indsendt

25. juli 2014

Først indsendt, der opfyldte QC-kriterier

25. juli 2014

Først opslået (Skøn)

29. juli 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

19. december 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. december 2014

Sidst verificeret

1. december 2014

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 20000

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Sjøgrens syndrom

Kliniske forsøg med Lid debridgement scaling

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Australia

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner